Srinivasa Reddy Bonam | Immunology | Young Scientist Award

Published on by Young Scientists Awards

Dr. Srinivasa Reddy Bonam | Immunology | Young Scientist Award

Senior Scientist | Indian Institute of Chemical Technology | India

Dr. Srinivasa Reddy Bonam is a distinguished scientist specializing in immunology, vaccine development, and pharmacology, with a significant research impact demonstrated by over 4,892 citations from 4,654 documents and an h-index of 29. He currently serves as an Assistant Professor at the Academy of Scientific and Innovative Research (AcSIR) and Senior Scientist at CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad, India. His extensive research experience spans advanced vaccine design, mRNA therapeutics, immunomodulators, and host-pathogen interactions. Dr. Bonam completed his Ph.D. at CSIR-IICT, Hyderabad, focusing on the immunopharmacological evaluation of novel glycopeptides and glycolipids as vaccine adjuvants and immunomodulators. His doctoral research led to the identification of multiple lead adjuvant candidates, with one licensed by Bharat Biotech International Ltd for emerging vaccines. After his Ph.D., he pursued postdoctoral research in Europe and the USA, contributing to the development of therapeutic peptides for autoimmune diseases at the University of Strasbourg, innovative immune regulation mechanisms in fungal infections and COVID-19 at INSERM Paris, and designing novel mRNA vaccines at the University of Texas Medical Branch (UTMB) in collaboration with Prof. Drew Weissman’s lab. Dr. Bonam has received honors including the Marie Curie Fellowship (self-denied), Outstanding Reviewer Awards from MDPI journals, and the Distinguished Alumni Award from CIPS. He serves as Editor-in-Chief of Advances in Pharmacology and Pharmacy, editorial board member of multiple journals, and peer reviewer for over 90 scientific journals. His pioneering contributions include patents on novel vaccine adjuvants and the development of Uttroside, a saponin-based vaccine adjuvant licensed to Bharat Biotech International Ltd. Driven by a commitment to next-generation vaccines and therapeutic strategies, Dr. Bonam continues to address emerging global health challenges through his high-impact research.

Profile: Scopus

Featured Publications

  1. Alameh, M.-G., Semon, A., Hu, H., Bonam, S. R., Maslanka, J. R., Weissman, D., & Zackular, J. P. (2024). A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science, 386(6717), 69–75.

  1. Bonam, S. R., Hazell, N. C., Mathew, M. J., Liang, Y., Zhang, X., Wei, Z., Alameh, M.-G., Weissman, D., & Hu, H. (2024). Innate and adaptive immune parameters following mRNA vaccination in mice. Vaccines, 12(5), 543.

  1. Ye, Z., Bonam, S. R., McKay, L. G. A., Plante, J. A., Walker, J., Zhao, Y., Huang, C., … Hu, H. (2023). Monovalent SARS-CoV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proceedings of the National Academy of Sciences, 120(52), e2311752120.

  2. Bonam, S. R., Platenburg, P. P., & Bayry, J. (2022). Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen-presenting cells. Frontiers in Immunology, 13, 7738.

  3. Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., … Hu, H. (2022). Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Science Translational Medicine, 14, eabq1945.